Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Dutasteride,Tadalafil
Therapeutic Area : Urology
Study Phase : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Will Dongkook Pharm Present New Combo Therapy for BPH?
Details : DKF-313 is a combination of dutasteride (5α-reductase inhibitor) and tadalafil (PDE5 inhibitor). It is being evaluated in phase 3 clinical trials for the treatment of benign prostatic hyperplasia.
Brand Name : DKF-313
Molecule Type : Small molecule
Upfront Cash : Not Applicable
September 26, 2023
Lead Product(s) : Dutasteride,Tadalafil
Therapeutic Area : Urology
Highest Development Status : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?